Volume 11, Number 1—January 2005
Research
Hepatitis C Virus Infection, Linxian, China1
Mingdong Zhang*, Xiu-Di Sun†, Steven D. Mark*, Wen Chen†, Lara Wong*, Sanford M. Dawsey*, You-Lin Qiao†, Joseph F. Fraumeni*, Philip R. Taylor*, and Thomas R. O’Brien*
Table
Prevalence of anti-HCV (by RIBA), HBsAg, and HBcAb in Linxian in 2000*
| N (%) | Anti-HCV % (95% CI) | p | HBcAb % (95% CI) | p | HBcAb and HBsAg % (95% CI) | p | |
|---|---|---|---|---|---|---|---|
| Overall | 9.6 (7.0–12.2) | 54.6 (50.2-59.0) | 6.4 (4.3-8.5) | ||||
| Age in 2000 (y) | |||||||
| <59 | 166 (33.2) | 8.4 (4.2–12.7) | 53.6 (46.0–61.2) | 5.4 (2.0–8.9) | |||
| 60–64 | 105 (21.0) | 13.3 (6.8–19.8) | 50.5 (40.9–60.0) | 6.7 (1.9–11.4) | |||
| 65–69 | 90 (18.0) | 11.1 (4.6–17.6) | 50.0 (39.7–60.3) | 4.4 (0.2–8.7) | |||
| 70–74 | 82 (16.4) | 6.1 (0.9–11.3) | 62.2 (51.7–72.7) | 8.5 (2.5–14.6) | |||
| >75 | 57 (11.4) | 8.8 (1.4–16.1) | 0.50 | 61.4 (48.8–74.0) | 0.34 | 8.8 (1.4–16.1) | 0.73 |
| Sex | |||||||
| Male | 200 (40.0) | 9.5 (5.4–13.6) | 58.0 (51.2–64.8) | 5.0 (2.0–8.0) | |||
| Female | 300 (60.0) | 9.7 (6.3–13.0) | 0.95 | 52.3 (46.7–58.0) | 0.21 | 7.3 (4.4–10.3) | 0.18 |
| Commune | |||||||
| Yaocun | 170 (34.0) | 11.8 (6.9–16.6) | 53.5 (46.0–61.0) | 6.5 (2.8–10.2) | |||
| Rencun | 95 (19.0) | 14.7 (7.6–21.9) | 64.2 (54.6–73.8) | 6.3 (1.4–11.2) | |||
| Donggang | 116 (23.2) | 2.6 (0.0–5.5) | 53.5 (44.4–62.5) | 6.0 (1.7–10.4) | |||
| Hengshui | 119 (23.8) | 9.2 (4.0–14.4) | 0.02 | 49.6 (40.6–58.6) | 0.18 | 6.7 (2.2–11.2) | 0.50 |
*HCV, hepatitis C virus; RIBA, recombinant immunoblot assay; HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core antibody; CI, confidence interval.
1Presented in part at the 11th Triennial International Symposium on Viral Hepatitis and Liver Disease, Sydney, Australia, April 4–10, 2003.
Page created: April 14, 2011
Page updated: April 14, 2011
Page reviewed: April 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.